These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1531593)

  • 1. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.
    Köhler C; Radesäter AC; Karlsson-Boethius G; Bryske B; Widman M
    J Neural Transm Gen Sect; 1992; 87(1):49-62. PubMed ID: 1531593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C; Hall H; Magnusson O; Lewander T; Gustafsson K
    Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors.
    Köhler C; Hall H; Gawell L
    Eur J Pharmacol; 1986 Jan; 120(2):217-26. PubMed ID: 3948920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO; Rosén L; Fuxe K
    Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H; Sällemark M
    Pharmacol Toxicol; 1987 May; 60(5):359-63. PubMed ID: 2886988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L; von Bahr C
    Acta Psychiatr Scand Suppl; 1990; 358():67-71. PubMed ID: 1978494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
    Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H; Ross SB
    Eur J Pharmacol; 1992 Jun; 226(2):157-61. PubMed ID: 1353452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O; Fowler CJ; Mohringe B; Wijkström A; Ogren SO
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr; 337(4):379-84. PubMed ID: 2900472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride.
    Köhler C; Radesäter AC
    Neurosci Lett; 1986 May; 66(1):85-90. PubMed ID: 2940480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.
    Köhler C; Hall H; Ogren SO; Gawell L
    Biochem Pharmacol; 1985 Jul; 34(13):2251-9. PubMed ID: 4015674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration.
    Magnusson O; Mohringe B; Thorell G; Lake-Bakaar DM
    Pharmacol Toxicol; 1987 May; 60(5):368-73. PubMed ID: 2886989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205-502.
    Closse A; Camps M; Wanner A; Palacios JM
    Brain Res; 1988 Feb; 440(1):123-32. PubMed ID: 2965955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.
    Hall H; Högberg T; Halldin C; Köhler C; Ström P; Ross SB; Larsson SA; Farde L
    Psychopharmacology (Berl); 1991; 103(1):6-18. PubMed ID: 1672460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic localization of the putative D4 dopamine receptor in rat brain.
    Defagot MC; Antonelli MC
    Neurochem Res; 1997 Apr; 22(4):401-7. PubMed ID: 9130250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.
    See RE; Toga AW; Ellison G
    J Neural Transm Gen Sect; 1990; 82(2):93-109. PubMed ID: 1977417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile.
    Ogren SO; Lundström J; Nilsson LB
    J Neural Transm Gen Sect; 1993; 94(3):199-216. PubMed ID: 8123230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative autoradiography of [3H]piquindone binding sites (dopamine D2 receptors) in rat brain.
    Nock B; Sedvall G; Mcewen BS
    Eur J Pharmacol; 1986 Mar; 121(3):387-93. PubMed ID: 3699100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.